Publicaciones en colaboración con investigadores/as de University of Pennsylvania (4)

2019

  1. Pembrolizumab in relapsed or refractory primary mediastinal large b-cell lymphoma

    Journal of Clinical Oncology

2018

  1. A novel FAS mutation with variable expressivity in a family with unicentric and idiopathic multicentric Castleman disease

    Blood Advances, Vol. 2, Núm. 21, pp. 2959-2963

  2. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

    The Lancet Oncology, Vol. 19, Núm. 9, pp. 1192-1204

2014

  1. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma

    Biomarker Research, Vol. 2, Núm. 1